Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Patients with inflammatory bowel disease had a higher risk for venous thromboembolism after surgery for colorectal cancer ...

Among patients with IBD, HLA-B27 positivity and higher UC disease activity were associated with an increased risk for SpA.

Patients with IBD who undergo colorectal cancer surgery have a higher risk for venous thromboembolism within 1 year after ...

One-day intensive course boosted first-year trainees’ overall confidence in IBD and raised comfort levels in discussing ...

GLP-1RA use, compared with basal insulin and DPP-4i use, was associated with lower risks for IBD and hospitalization in type 2 diabetes.

Clostridioides difficile risk is significantly higher in Korean patients with inflammatory bowel disease (IBD), which is comparable to the trend observed in Western patients with IBD. There is an ...

Researchers compare the different effects of pro-inflammatory dietary patterns on inflammatory bowel disease severity.

Tempus AI stock surged to a record-high Monday after the Food and Drug Administration cleared its new device to help ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...